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Rapid diagnostic tests for detecting emerging antibiotic resistance are mostly available and should
be used now.
Clinically-signicant multidrug-resistant bacteria are increasingly reported within enterobacterial species
(e.g., Escherichia coli, Klebsiella pneumoniae, Enterobacter spp) and also within the two nosocomial Gram-
negative pathogens, namely Pseudomonas aeruginosa and Acinetobacter baumannii [1].
The antibiotic resistance traits that are currently widespread in these Gram-negatives are mostly extended-
spectrum ß-lactamases (ESBL) and carbapanemases producers [2, 3]. The ESBLs confer resistance to all b-
lactams, with the exception of cephamycins and carbapenems, while carbapenemases confer resistance to
virtually all b-lactams including carbapenems [2, 3]. In addition, ESBL and carbapenemase-producers are
often resistant to non-related broad-spectrum antibiotics such as aminoglycosides and uoroquinolones.
Among the latest emerging antibiotic resistance traits, polymyxin resistance and pandrug resistance to
aminoglycosides are also of concern [4, 5].
Historically, diagnosis and evaluation of antimicrobial resistance has been based on the culture of
microorganisms. This ‘old-fashioned’ way of testing antibiotic susceptibility has proven to be quite accurate;
however, it is time consuming, especially for slow-growing organisms (from 24 hour rapid-growth bacteria
to several days), and it is neither adapted to adequate antibiotic stewardship nor to epidemiological
purposes including the identication of the resistance mechanism(s).
As an example, bloodstream infections have the highest impact in term of morbidity, mortality and health
care costs [6]. Empirical antibiotic therapy is the rule for treating severe sepsis and a timely and adequate
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Detection and resultant control of antimicrobial resistance has therefore become a major issue in clinical
microbiology. In the eld of infectious diseases, we are currently witnessing a revolution in the development
of diagnostic techniques for diseases and their resistance traits. The rapid diagnostic techniques available
for detection of antibiotic resistance are based on molecular biology, biochemistry, physics, immunology
and rapid culture techniques. We believe use of those techniques now may contribute to an optimal
therapeutic choice of antibiotics for treating infections due to ESBL, carbapenemase producers, polymyxins
and pan aminoglycoside resistant Gram-negatives as well as controlling their spread in nosocomial settings.
Use of molecular biology and in particular PCR-based techniques is nowadays the key approach for rapid
and accurate identication of many etiological agents, including those considered to be dicult, or even
impossible, to cultivate [9].
The main advantages of molecular techniques are sensitivity, specicity and rapidity. Among the currently
used molecular-based techniques there are real-time PCR protocols that may target clinically-relevant
antibiotic resistance genes. Such PCR-based detection methods of antimicrobial resistance are now
commercially available and provided by many companies. Many of them are easy to implement and do not
require outstanding expertise.
However, the main caveat of these tests is that they remain relatively expensive, making them aordable
only for certain countries, but unaordable for many others where the problem of resistance is extremely
high.
Furthermore, it is very important to highlight that these tests cannot fully substitute the antibiogram since
they only target some given resistance determinants and do not evaluate the real susceptibility of the
isolate to a large variety of drugs. Indeed, a good correlation between the gene identication on one hand,
and the resistance phenotype on the other hand, is not always observed (gene expression and modulation).
In addition, the same resistance phenotype may result from several mechanisms that can be combined and
therefore is dicult to predict through molecular approaches.
Moreover, as soon as a novel resistance gene emerges that is not included in the screening then antibiotic
susceptibility testing based only on gene identication is obviously no longer reliable. Finally, it is worth
highlighting that molecular methods are overall ecient genetic tools for the prediction of resistance, but
are conversely not adapted to the prediction of susceptibility, with is a major drawback when considering
antibiotic stewardship.
New tests based on biochemistry, immunology and rapid cultures have now been developed. This is the
case with biochemical detection of carbapenemase activity (Rapid Carba NP test; bioMérieux, La Balme-Les-
Grottes, France) and the detection of the ESBL activity (Rapid ESBL NP test) [10–12]. The main advantages of
these tests are their speed (30 minutes) and low cost, in contrast to most other known techniques.
In addition, a signicant advantage is that they can be used not only for bacterial cultures but also directly
for blood and urine [13–15]. Consequently, they can now be used to optimize the stewardship of
carbapenems considering that those molecules hydrolyzed by carbapenemases are spared by ESBLs. As an
example, in a context of increased prevalence of ESBL producers, rapidly conrming the lack of such
determinant in a given isolate means that broad-spectrum cephalosporins can be safely used, and that the
last-resort carbapenems can be spared.
MALDI-TOF – a technology based on mass spectrometry coupled with a light analyzer – is now widely used
for identication of microorganisms at the species level. Recent studies have shown that MALDI-TOF can
also be used for the purpose of detecting resistance to antibiotics based on the detection of enzymatic
activity, such as that of carbapenemases usually correlating with resistance to carbapenems [16]. This is an
interesting use of this technique; however, it still needs to be precisely tuned in a lab and currently requires
30 minutes to 3 hours to get the results.
Immunological lateral ow techniques have recently been successfully implemented to detect
carbapenemase producers (those producing enzymes such as KPC and OXA-48) from bacterial cultures











Rapid culture techniques have been recently developed for detection of polymyin and pan-aminoglycoside
resistance in Enterobacteriaceae. The Rapid Polymyxin NP test (Rapid Polymyxin NP; ELITech Microbiology,
Puteaux, France) may detect any polymyxin-resistant isolate, the corresponding resistance mechanisms
being either chromosome- or plasmid-encoded (mcr-1, mcr-2) [18]. The Rapid Aminoglycoside NP test
detects pandrug resistance to aminoglycosides resulting from the expression of 16S rRNA methylases [19].
Results of both rapid tests are obtained within 1–2 hours, either using bacterial cultures or blood cultures
as samples [20].
Advances in high-throughput sequencing technologies, often named next-generation sequencing, recently
opened signicant research pathways, particularly in the eld of molecular diagnostics of antimicrobial
resistance [9]. The latest development of next-generation sequencing will be (or is) high-resolution
epidemiology that will replace conventional epidemiological tools such as pulsed-eld gel electrophoresis
and multi-locus sequence typing.
Since very few novel antibiotic molecules will be marketed in the near future, control of antimicrobial
resistance spread is primarily based on their rapid diagnosis. Actually, an early detection of the major
resistance traits as described above is absolutely crucial for controlling spread. In addition, we believe that
many of the rapid diagnostic techniques that are available may be used as companion diagnostics (precise
medicine) to optimize the use of novel molecules such as the combinations of ß-lactams and ß-lactamase
inhibitors. Use of those novel and rapid diagnostic techniques may contribute to preventing antibiotic
overuse or misuse.
The revolution we are currently facing in rapid diagnostic techniques may allow us to optimize the
management of treatments for infections caused by multidrug resistant bacteria and also contribute to
controlling their spread. Rapid diagnostics contribute to the overall reduction of broad-spectrum antibiotic
use and consequently could slow down the rise of resistant bacteria. This means we could expect to deal
with such diagnostics either in primary care and hospital setting situations.
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